- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02551250
Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis (MAGNUS-HCC)
Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging as a Surveillance Test for Hepatocellular Carcinoma in Patients With Liver Cirrhosis
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Hepatocellular carcinoma (HCC) is one of the major complications in patients with chronic liver disease. The prognosis of HCC relies on the extent of disease at the time of diagnosis. Hence to detect cancer at an earlier stage, a regular surveillance test is important for the subjects with a high risk of developing cancer. Current guidelines recommend a regular surveillance using ultrasonography (US) at a 6 month-interval. Ultrasonography is a non-invasive and safe procedure, yet it is limited by the skills of the operator and it is often difficult to differentiate cancer from regenerating nodules especially in atrophied cirrhotic liver. According to a recent meta-analysis, the overall sensitivity and specificity of detecting liver cancer using ultrasonography were both over 90%, however the sensitivity was decreased to 60% in detecting early lesions in which surgery or liver transplantation is indicated. Of note, addition of alpha feto protein(AFP) to ultrasonography also failed to increase the sensitivity in detecting small cancers. Taken together, there is a need to develop a new surveillance test with an improved sensitivity and specificity.
Recently, a retrospective study reported that CT or MRI showed a better sensitivity than ultrasonography in detecting early liver cancer. However, performing CT as a surveillance test is limited by frequent exposure to radiation and contrast-dye agent. Although MRI does not have the risk of radiation-exposure, it is limited by the high cost and limited availability. On the contrast, non-contrast MRI offers a cost that is comparable to US and an absence of exposure to radiation or contrast-dye agent, which suggests non-contrast MRI as a good alternative surveillance tool for early detection of HCC. Therefore, in this prospective trial, the investigators will investigate the usefulness of biannual ultrasonography versus annual non-contrast magnetic resonance imaging for surveillance of hepatocellular carcinoma.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Seoul, Korea, Republik von
- Seoul National University Hospital
-
Seoul, Korea, Republik von
- Samsung Medical Center
-
Seoul, Korea, Republik von, 06591
- Seoul St.Mary's Hospital
-
Seoul, Korea, Republik von
- Korean University Guro Hospital
-
Suwon, Korea, Republik von
- St.Vincent's Hospital
-
Uijeongbu, Korea, Republik von
- Uijeongbu St.Mary's Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Male or female subject older than 40 years of age at the enrollment
- Fulfill below conditions A and B
A. The evidence of cirrhosis of any etiology within 12 months prior to screening Definition of cirrhosis by any of following methods
- Histologically by liver biopsy;
Non-histologically by evidence of portal hypertension in the presence of chronic liver disease;
Evidence of portal hypertension, including any of followings;
- The identification of splenomegaly on ultrasonography, CT, or MRI examinations with typical features of cirrhosis
- The identification of esophageal or gastric varices on endoscopic examination
B. Risk Index larger than 2.33; Risk Index = 1.65 (if the prothrombin activity is <=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is <=100,000/mm3) + 0.74 (if the presence of HCV is positive).
Exclusion Criteria:
- Presence of liver cancer or other intrahepatic malignancy
- Has a history of malignancy within previous 5 years
- Is pregnant or breast-feeding
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Study
Surveillance of HCC by biannual ultrasonography AND annual noncontrast MRI
|
liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s
liver ultrasonography for HCC screening performed by experienced sonologists
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
sensitivity for detecting HCC
Zeitfenster: 3 years
|
sensitivity for detecting HCC
|
3 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
survival of the patients who developed HCC on follow-up period
Zeitfenster: years
|
survival of the patients who developed HCC on follow-up period
|
years
|
false referral rate for HCC
Zeitfenster: 3 years
|
false referral rate for HCC
|
3 years
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Joon-Il Choi, Seoul St. Mary's Hospital
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Kim YK, Kim YK, Park HJ, Park MJ, Lee WJ, Choi D. Noncontrast MRI with diffusion-weighted imaging as the sole imaging modality for detecting liver malignancy in patients with high risk for hepatocellular carcinoma. Magn Reson Imaging. 2014 Jul;32(6):610-8. doi: 10.1016/j.mri.2013.12.021. Epub 2014 Jan 13.
- Kim HA, Kim KA, Choi JI, Lee JM, Lee CH, Kang TW, Ku YM, Lee SL, Park YS, Yoon JH, Kim SH, Choi MH. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol. BMC Cancer. 2017 Dec 21;17(1):877. doi: 10.1186/s12885-017-3819-y.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- Pathologische Prozesse
- Neubildungen nach histologischem Typ
- Neubildungen
- Neubildungen nach Standort
- Adenokarzinom
- Neubildungen, Drüsen und Epithelien
- Neoplasmen des Verdauungssystems
- Leberkrankheiten
- Lebertumoren
- Fibrose
- Karzinom
- Karzinom, hepatozellulär
- Leberzirrhose
Andere Studien-ID-Nummern
- 1520160
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur annual noncontrast MRI
-
Assiut UniversityUnbekanntMultiple Sklerose
-
Fondation Ophtalmologique Adolphe de RothschildRekrutierungOptimierte MRT-SequenzenFrankreich
-
Institut National de la Santé Et de la Recherche...Abgeschlossen
-
University of MilanAbgeschlossenKnie-KnochenmarksläsionenItalien
-
Vanderbilt UniversityNational Institutes of Health (NIH)ZurückgezogenHypoxische ischämische EnzephalopathieVereinigte Staaten
-
Abbott Medical DevicesBeendet
-
Fondation LenvalAbgeschlossen
-
Centre Georges Francois LeclercAktiv, nicht rekrutierendAdenokarzinom der ProstataFrankreich
-
Assistance Publique - Hôpitaux de ParisAbgeschlossenEpilepsie im Kindesalter [Pyknolepsie]Frankreich
-
London Health Sciences CentreAbgeschlossen